We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+10.97%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.05B
AUM Growth
+$206M
Cap. Flow
-$716M
Cap. Flow %
-14.18%
Top 10 Hldgs %
83.23%
Holding
98
New
29
Increased
15
Reduced
26
Closed
6

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$8.14M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$7.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$6.05M
4
ATRA icon
Atara Biotherapeutics
ATRA
+$4.89M
5
NTB icon
Bank of N.T. Butterfield & Son
NTB
+$4.86M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$699M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.1M
3
C icon
Citigroup
C
+$10.6M
4
BABA icon
Alibaba
BABA
+$9.27M
5
APTV icon
Aptiv
APTV
+$8.43M

Sector Composition

Rank Sector Weight
1 Consumer Staples 41.33%
2 Healthcare 28.74%
3 Miscellaneous 21.25%
4 Consumer Discretionary 7.22%
5 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
26
Nektar Therapeutics
NKTR
$2.34B
$17.2M 0.34%
66,667
-26,666
-29% -$6.87M
PFE icon
27
CALL
Pfizer
PFE
$158B
$16.9M 0.34%
+527,000
New +$17.6M
JPM icon
28
CALL
JPMorgan Chase
JPM
$931B
$16.6M 0.33%
250,000
– –
IBM icon
29
CALL
IBM
IBM
$235B
$15.9M 0.31%
104,600
– –
BAC icon
30
Bank of America
BAC
$416B
$15.7M 0.31%
1,000,000
-100,000
-9% -$1.49M
WFC icon
31
CALL
Wells Fargo
WFC
$273B
$15.5M 0.31%
+350,000
New +$16.7M
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$14.1M 0.28%
1,900,000
+650,000
+52% +$4.39M
SRPT icon
33
Sarepta Therapeutics
SRPT
$2.16B
$12.3M 0.24%
+200,000
New +$6.05M
MS icon
34
Morgan Stanley
MS
$337B
$11.2M 0.22%
350,000
-50,000
-13% -$1.49M
APTV icon
35
Aptiv
APTV
$9.3B
$10.7M 0.21%
150,000
-125,000
-45% -$8.43M
TSLA icon
36
Tesla
TSLA
$1.42T
$10.2M 0.2%
750,000
-375,000
-33% -$5.41M
INCY icon
37
CALL
Incyte
INCY
$24.8B
$9.43M 0.19%
+100,000
New +$8.43M
SAGE
38
DELISTED
Sage Therapeutics
SAGE
$9.21M 0.18%
+200,000
New +$8.14M
AVXS
39
DELISTED
AveXis, Inc. Common Stock
AVXS
$8.24M 0.16%
200,000
+38,100
+24% +$1.45M
MET icon
40
MetLife
MET
$61.7B
$7.78M 0.15%
196,350
-84,150
-30% -$3.16M
AMAG
41
DELISTED
AMAG Pharmaceuticals
AMAG
$7.35M 0.15%
+300,000
New +$7.5M
IONS icon
42
CALL
Ionis Pharmaceuticals
IONS
$8.55B
$7.33M 0.15%
+200,000
New +$6.26M
CCXI
43
DELISTED
ChemoCentryx, Inc.
CCXI
$7.25M 0.14%
1,200,000
+300,000
+33% +$1.42M
AGEN
44
Agenus
AGEN
$312M
$7.18M 0.14%
50,950
– –
ALNY icon
45
CALL
Alnylam Pharmaceuticals
ALNY
$33.5B
$6.78M 0.13%
100,000
-200,000
-67% -$14.1M
JD icon
46
CALL
JD.com
JD
$36.8B
$6.52M 0.13%
250,000
– –
HZNP
47
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.35M 0.13%
350,000
– –
XLRN
48
DELISTED
Acceleron Pharma
XLRN
$6.33M 0.13%
175,000
+75,000
+75% +$2.48M
MCRB icon
49
Seres Therapeutics
MCRB
$50.3M
$6.14M 0.12%
25,000
+9,500
+61% +$3.33M
SRPT icon
50
CALL
Sarepta Therapeutics
SRPT
$2.16B
$6.14M 0.12%
100,000
– –
1
2
3 4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2016 Portfolio in Review

As of Q3 2016, Artal Group held 98 positions worth $5.05B, up 4.3% from $4.84B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $716M in Q3 2016, closing 6 positions and reducing 26 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $20.1M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 41% of assets, down from 56% a quarter earlier, followed by Healthcare and Miscellaneous.

Against the trend, Artal Group opened a new position in Sage Therapeutics worth $9.21M.

  • Artal Group's largest Q3 2016 buy was Sage Therapeutics: 200,000 shares worth $9.21M.
  • Artal Group added most to Amicus Therapeutics in Q3 2016, an estimated $4.39M increase.
  • Artal Group's biggest Q3 2016 reduction was Blue Buffalo Pet Products, Inc, cutting an estimated $699M.
  • Artal Group fully exited Regeneron Pharmaceuticals in Q3 2016, selling an estimated $20.1M.
  • Artal Group's ten largest holdings make up 83% of its $5.05B portfolio in Q3 2016.
  • Artal Group opened 29 new positions and closed 6 in Q3 2016.
  • Artal Group's portfolio value rose 4.3% quarter-over-quarter to $5.05B.

Based on Artal Group's 13F filing for Q3 2016, filed 14 Nov 2016.